

REMARKS

Entry of the foregoing, reexamination and further and favorable reconsideration of the subject application in light of the following remarks pursuant to and consistent with 37 C.F.R. § 1.112, are respectfully requested.

By the foregoing amendment, claims 1-11 have been canceled without prejudice or disclaimer to the subject matter recited therein and new claims 16-30 have been added. New claims 16-26 correspond to originally filed claims 1-11. These newly presented claims are not intended to narrow the scope of the previous claims or any element recited therein. New claims 27-30 are directed to a process for preparing the glycoprotein as set forth in claim 1 and the inhibitor as set forth in claim 22.¹ Support for these newly presented claims can be found throughout the originally filed application, including the claims. Hence, no new matter has been added.

Turning now to the Official Action, the Examiner has required applicants to provide an English language translation of Japanese Application No. 2000-113913 for which the benefit of priority has been properly claimed. Accordingly, applicants have enclosed herewith the required English language translation.

Applicants hereby affirm their election, **with traverse**, of claims 1-11 (Group I).

According to M.P.E.P. § 803, a restriction requirement should not be made unless there is a serious burden on the Examiner. This is true even when other proper grounds

¹ New claims 27-30 should not be restricted from elected claims 1-11 (which now correspond to new claims 16-26) as such claims are properly linked as products and processes of preparing such products.

exist. Here, no serious burden exists because a search of the claims relating to methods of using the glycoprotein, claims 12-13 (Group II) and claims 14-15 (Group II) would necessarily include the glycoprotein of Group I. Further, claims 12-15 are properly linked as products and process of using such products. Therefore, applicants respectfully request that the Examiner withdraw the restriction requirement and examine claims 12-15 along with elected Group I.

Alternatively, according to 1184 OG 86 and M.P.E.P. § 821.04, when elected product claims are allowed and non-elected process claims depend from the product claims or otherwise include all limitations of the product claims, the rejoinder of the process claims is in order. Therefore, if the restriction requirement is maintained, eventual rejoinder of the process claims (claims 12-15) with the allowed product claims should occur.

The Examiner has objected to claims 1-11 for use of the terms “glycoprotien” and “albumen.” Use of the term “glycoprotien” in the originally filed claims was an inadvertent and obvious typographical. Thus appropriate correction has been made in connection with the newly presented claims. However, use of the term “albumen” is not in error as such term means the white of an egg. Applicants have enclosed herewith an excerpt from the American Heritage College Dictionary which defines the term “albumen” in this regard. The Examiner’s attention is also directed to U.S. Patent No. 6,235,709 which utilizes this term as well. In light of the above, the Examiner is respectfully requested to withdraw such objections to the claims.

The Examiner has further objected to use of the term "*Helicobacter pylori*" since it contains underlining. The newly presented claims make use of italics as opposed to underlining in connection with the term "*Helicobacter pylori*."

Claim 1 has been rejected under 35 U.S.C. § 101 because the claimed invention is allegedly directed to non-statutory subject matter. This rejection is respectfully traversed. Claim 1 has been canceled thereby rendering the rejection moot. To the extent that this rejection may still apply to any of the newly presented claims, applicants respectfully maintain its traversal. It is clear from the claim itself that such subject matter is not directed to a product of nature as claim 1 specifically recites that the glycoprotein "is obtained by isolation and purification from a glycoprotein-containing substance using a method which utilizes specific adsorption to *Helicobacter pylori*." Thus, insertion of the phrase "isolated or purified"² before the term glycoprotein within the claim would be redundant and unnecessary. Accordingly, withdrawal of this rejection is respectfully requested.

Claims 1, 4-6, and apparently claims 8-9 and 11, have been rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for purportedly failing to particularly point out and distinctly claim the subject matter which applicants regard as the invention. This rejection is respectfully traversed.

² The Examiner is respectfully requested to clarify whether the entire phrase "isolated or purified" should be inserted or whether applicants could choose between the insertion of the term "isolated" or the term "purified."

As mentioned above, claims 1, 4-6, 8-9 and 11 have been canceled without prejudice or disclaimer to the subject matter recited therein. Thus, the rejection is rendered moot. To the extent that this rejection may apply to any of the newly presented claims, applicants provide the following remarks traversing such rejection.

In particular, the Examiner has rejected claim 1 for recitation of the phrase "which specifically binds" because the definition of "specifically" is allegedly unclear as to the degree of affinity or binding. In the present specification, the term "specifically" is used in a way commonly used by those skilled in the art, namely it means that a substance exhibits a characteristic reactivity with a particular substance. Therefore, "specifically binds" means that the partner for binding is a particular one and does not mean the degree of affinity or binding. In the present case, the claimed glycoprotein reacts predominately with urease of *Helicobacter pylori*. The tests at pages 17 and 18 are not intended to define specific of non-specific. The results of inhibition test of urease adherence show that the claimed glycoprotein exhibits higher inhibitory activity than high molecular weight whey or albumen protein concentrate, indicating that the glycoprotein which specifically binds to urease of *Helicobacter pylori* can be selected by the isolation and purification using a method which utilizes specific adsorption to *Helicobacter pylori*.

Claims 4-6 have also been rejected as the phrase "derived from" allegedly renders the claims indefinite. For example, originally filed claim 4 recited that the glycoprotein-containing substance is derived from whey of bovine milk. This means that whey of bovine milk is treated by means of known fractionation or concentration techniques to

obtain a fraction containing glycoprotein concentrated as compared to the original whey. To expedite prosecution in the subject application and not to acquiesce to the Examiner's rejection, newly presented claims 19-21, which correspond to the subject matter of canceled claims 4-6, recite that the glycoprotein-containing substance is " . . . obtained from"

Claims 8-9 have been allegedly rendered indefinite for use of the term "and/or." To expedite prosecution in the subject application and not to acquiesce to the Examiner's rejection, newly presented claims 23-24, which correspond to the subject matter of canceled claims 8-9, recite "or."

Claims 8-9 and 11 have also been allegedly rendered indefinite for recitation of the phrase "a disease." To expedite prosecution in the subject application and not to acquiesce to the Examiner's rejection, newly presented claims 23-24 and 26, which correspond to the subject matter of canceled claims 8-9 and 11, recite "a gastrointestinal disease."

In view of the above, the Examiner is respectfully requested to withdraw the rejection under 35 U.S.C. § 112, second paragraph.

Furthermore, claims 1-11 have been rejected under 35 U.S.C. § 102(e) as purportedly being anticipated by Kodama et al. (U.S. Patent No. 6,235,709, hereinafter "the '709 patent"). This rejection is respectfully traversed.

As mentioned above, claims 1-11 have been canceled without prejudice or disclaimer to the subject matter recited therein. Thus, the rejection is rendered moot. To

the extent that this rejection may apply to any of the newly presented claims, applicants provide the following remarks traversing such rejection.

The subject application was filed after November 29, 2000 and thus is subject to the current version of 35 U.S.C. § 102(e) as follows:

(e) [A person shall be entitled to a patent unless] the invention was described in --

(1) . . . ; or

(2) a patent granted on an application for patent **by another** filed in the United States before the invention by the applicant for patent

Emphasis added.

As described in section 2136.04 of the M.P.E.P., the terminology “by another” means other than applicants. In other words, a different inventive entity.

~~In the present situation, the subject application lists Yoshikatsu Kodama and Nobutake Kimura as the inventors. The ‘709 patent also lists Yoshikatsu Kodama and Nobutake Kimura as the inventors. As all of the inventors are the same, the inventive entity is not different. Accordingly, the ‘709 patent is not a proper reference under 35 U.S.C. § 102(e).~~

Moreover, applicants submit that the ‘709 patent fails to disclose every element of the claimed invention in the form literally defined in the claims. *See, e.g., Hybritech Inc. v. Monoclonal Antibodies, Inc.*, 231 U.S.P.Q. 81, 90 (Fed. Cir. 1986) (indicating that for prior art to be anticipatory, every element of the claimed invention must be disclosed in a single item of prior art in the form literally defined in the claim). Regarding the instant

rejection, the '709 patent fails to disclose the glycoprotein obtained by the isolation and purification method which utilizes specific adsorption to *Helicobacter pylori* urease.

In the Official Action the Examiner has stated that "the process steps are given no weight in claim 1 because the process steps do not materially change the glycoprotein and the patentability is based on the product per se." Applicants respectfully disagree because it is believed that the process steps do in fact change the composition of the claimed glycoprotein. The process steps in claim 16, which corresponds to canceled claim 1, expresses that the glycoprotein of the present invention is obtained from a glycoprotein-containing substance such as high molecular weight whey protein concentrate or high molecular weight albumen protein concentrate, which contains various types of glycoproteins having different configurations and properties, by the isolation and purification using a method which utilizes specific adsorption to *Helicobacter pylori*. The '709 patent does not disclose the glycoprotein (mucin) obtained by isolation and purification using a method which utilizes specific adsorption to *Helicobacter pylori* urease.

In view of the above, the Examiner is respectfully requested to withdraw the rejection under 35 U.S.C. § 102(e).

From the foregoing, further and favorable action in the form of a Notice of Allowance is respectfully requested and such action is earnestly solicited.


In the event that there are any questions relating to this Amendment and Reply, or the application in general, it would be appreciated if the Examiner would telephone the

Application Serial No. 09/833.637
Attorney's Docket No. 011900-309

undersigned attorney concerning such questions so that prosecution of this application may
be expedited.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Susan M. Dadio
Registration No. 40,373

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: January 22, 2001

9-833637
\$5-

THE AMERICAN HERITAGE COLLEGE DICTIONARY

THIRD EDITION

n·a·r·y



HOUGHTON MIFFLIN COMPANY
Boston • New York

Words are included in this Dictionary on the basis of their usage. Words that are known to have current trademark registrations are shown with an initial capital and are also identified as trademarks. No investigation has been made of common-law trademark rights in any word, because such investigation is impracticable. The inclusion of any word in this Dictionary is not, however, an expression of the Publisher's opinion as to whether or not it is subject to proprietary rights. Indeed, no definition in this Dictionary is to be regarded as affecting the validity of any trademark.

American Heritage and the eagle logo are registered trademarks of Forbes Inc. Their use is pursuant to a license agreement with Forbes Inc.

Copyright © 1993 by Houghton Mifflin Company.
All rights reserved.

No part of this work may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying and recording, or by any information storage or retrieval system without the prior written permission of Houghton Mifflin Company unless such copying is expressly permitted by federal copyright law. Address inquiries to Reference Permissions, Houghton Mifflin Company, 222 Berkeley Street, Boston MA 02116.

0-395-67161-2 (UPC)

Library of Congress Cataloging-in-Publication Data

The American heritage college dictionary. —3rd ed.

p. cm.

ISBN 0-395-66917-0 (plain edge). —ISBN 0-395-44638-4 (thumb edge). —ISBN 0-395-66918-9 (deluxe binding).

1. English language—Dictionaries. 2. Americanisms.

PE1628.A6227 1993

423—dc20

92-42124

CIP

Manufactured in the United States of America

For information about this and other Houghton Mifflin trade and reference books and multimedia products, visit The Bookstore at Houghton Mifflin on the World Wide Web at (<http://www.hmco.com/trade/>).

Al·ba·ce·te (äl'ba-sä'té, äl'vä-ché'té). A city of SE Spain WSW of Valencia. Pop. 121,909.

al·ba·core (äl'ba-kör', -kör') *n.*, *pl.* albacore or -cores. A large marine fish (*Thunnus alalunga*) having edible flesh. [Port. *albacor* < Ar. *al-bakrah*: *al*, the + *bakrah*, young camel.]

Al·ba·lon·ga (äl'ba löng'ga, löng'-). A city of ancient Latium in central Italy SE of Rome; founded before 1100 a.c. and the legendary birthplace of Romulus and Remus.

Al·ba·ni·a (äl'ba-né-a, -bän'ya, öl-). A country of SE Europe on the Adriatic Sea; became a republic in 1925. Cap. Tiranë. Pop. 2,841,300.

Al·ba·ni·an (äl'ba-né-an, -bän'yan, öl-) *adj.* Of or relating to Albania or its people, language, or culture. — *n.* 1. A native or an inhabitant of Albania. 2. The Indo-European language of the Albanians.

Al·ba·no (äl'ba-nó). A lake of central Italy SE of Rome in an extinct volcanic crater.

Al·ba·ny (äl'ba-né). 1. A city of SW GA SE of Columbus. Pop. 78,122. 2. The cap. (since 1797) of NY, in the E part on the Hudson R.; founded in the early 17th cent. as Fort Orange and renamed Albany in 1664. Pop. 101,082. 3. A city of NW OR on the Willamette R. S. of Salem. Pop. 29,462.

Albany River. A river rising in W Ontario, Canada, and flowing c. 982 km (610 mi) to James Bay.

al·ba·tross (äl'ba-trós', -trós') *n.*, *pl.* albatross or -trosses. 1. Any of several large web-footed birds constituting the family Diomedidae, chiefly of the oceans of the Southern Hemisphere. 2.a. A constant, worrisome burden. b. An obstacle to success. [Prob. alteration (influenced by Lat. *albus*, white) of *alcatraz*, pelican < Port. or Sp. *alcatraz* < Ar. *al-gattās*: *al*, the + *gattās*, white-tailed sea eagle. Sense 2, after the albatross in *The Rime of the Ancient Mariner* by Samuel Taylor Coleridge, which the mariner killed and had to wear around his neck as a penance.]

al·ba·do (äl'ba-dó) *n.*, *pl.* -dos. The fraction of incident electromagnetic radiation reflected by a surface. [Lat. *albēdō*, whiteness < Lat. *albus*, white. See *albho*·.]

Al·bee (äl'be, öl', -l'), Edward Franklin. b. 1928. Amer. playwright best known for *Who's Afraid of Virginia Woolf?* (1962).

al·be·it (öl'be'it, öl-) *conj.* Even though; although; notwithstanding: *a clear albe it cold day.* [ME *al be it*: *al*, even if; see *al* + *be*, subjunctive of *be*, to be; see *se* + *it*; see *tr*.]

Al·be·mar·le Sound (äl'ba-mär'l'). A large body of generally fresh water in NE NC separated from the Atlantic by a narrow barrier island.

Al·be·niz (äl'ba-nés', -äl-), Isaac. 1860–1909. Spanish composer of piano works based on Spanish folk music.

Al·bers (äl'berz, öl'-), Josef. 1888–1976. German-born Amer. painter whose works include *Homage to the Square* (1950–59).

Al·bart (äl'bart), Prince. 1819–61. German-born consort (1840–61) of Victoria.

Albert I. 1875–1934. King of the Belgians (1909–34) who led the forces that reconquered Belgium (1918) during World War I.

Albert, Lake. Also **Mo·bu·to Lake** (mö-bö'tó) or **Albert Nyan·za** (nä-än'za, nyän'-). A shallow lake of E-central Africa in the Great Rift Valley between Uganda and Zaire.

Al·ber·ta (äl'bér'ta). A province of W Canada between British Columbia and Saskatchewan; joined the confederation in 1905. Cap. Edmonton. Pop. 2,237,724. — **Al·ber'tan** *adj.* & *n.*

Albert Lea (læ). A city of S MN near the IA border S of Minneapolis. Pop. 18,310.

Albert Nile (nil). Part of the upper Nile R. in NW Uganda.

Al·ber·tus Mag·nus (äl'bür'tas mäg'nos), Saint. 1206?–80. German religious philosopher.

al·bes·cent (äl'bés'ant) *adj.* Becoming white; whitish. [Lat. *albescens*, *albescens*, pr. part. of *albescere*, to become white < *albus*, white. See *albho*·.]

Al·bi·gen·ses (äl'ba-jén'séz') *pl.* *n.* The members of a Catholic religious sect of southern France in the 12th and 13th centuries, condemned for heresy and persecuted during the Inquisition. [Med. Lat., *pl.* of *Albigensis*, inhabitant of *Albige*, Albi, a town of S France.] — **Al·bi·gen'stan** (-shan, -sén) *adj.* — **Al·bi·gen'stan·ism** *n.*

al·bi·nism (äl'bi-niz'm) *n.* 1. Congenital absence of normal pigmentation or coloration. 2. The condition of being an albino. [Fr. *albinisme* < Ger. *Albinismus* < *Albino*, albino < Port. See *aluno*.] — **al·bi·nistic** *adj.*

al·bi·no (äl'bi-nó) *n.*, *pl.* -nos. 1. A person or an animal lacking normal pigmentation, so that the skin and hair are abnormally white and the eyes have a pink or blue iris and a deep-red pupil. 2. A plant that lacks chlorophyll. [Port. < *albo*, white < Lat. *albus*. See *albho*·.]

Al·bi·on (äl'bi-on). England or Great Britain.

al·bite (äl'bit) *n.* A white feldspar, NaAlSi₃O₈, that is one of the common rock-forming plagioclase group. [Lat. *albus*, white; see *albho*· + -*m*·.] — **al·bit'ic** (-bit'ik), **al·bit'ic** (-i-ik) *adj.*

Al·bo·in (äl'boin, -bō-in). d. 572. King of the Lombards (563?–572) who led the Germanic invasion of Italy.

Al·borg also **Aal·borg** (äl'börg'). A city of N Denmark NNE of Århus; chartered 1342. Pop. 154,840.

Al·bright (äl'brit, öl'-), Horace Marden. 1890–1987. Amer. conservationist and cofounder of the National Park Service.

al·bum (äl'bəm) *n.* 1. A book with blank pages for the insertion and preservation of collections, as of stamps. 2.a. A set of phonograph records stored together. b. The holder for such records. c. One or more 12-inch long-playing records. 3. A printed collection of musical compositions, pictures, or literary selections. 4. A tall printed book, often having profuse illustrations and short, sentimental texts. [Lat., blank tablet < neut. of *albus*, white. See *albho*·.]

al·bu·man (äl-byōd'mən) *n.* 1. The white of an egg. 2. See *albumin*. [Lat. *albumen* < *albus*, white. See *albho*·.]

al·bu·min (äl-byōd'min) *n.* A class of simple water-soluble proteins found in egg white, blood serum, milk, and other animal and plant juices and tissues. [ALBUM(EN) + -*in*.] — **al·bu·mi·nous** *adj.*

al·bu·mi·noid (äl-byōd'mə-noid') *n.* See *scleroprotein*. — *adj.* also **al·bu·mi·noid·al** (-byōd'mə-noid'l). Composed of or resembling albumin.

al·bu·mi·nu·ri·a (äl-byōd'mə-nōōr'i-ä, -nyōōr-) *n.* The presence of albumin in the urine. — **al·bu·mi·nu·ric** (-nōōr'ik, -nyōōr'ik) *adj.*

al·bu·mose (äl'by-mōs', -mōz') *n.* A class of substances derived from albumins and formed by the enzymatic breakdown of proteins during digestion. [Fr.: *albumine*, albumin; see *ALBUM* + -*ose*, -*ose*; see -*ose*·.]

Al·bu·quer·que (äl'ba-kūr'ké). A city of central NM on the Rio Grande SW of Santa Fe; founded 1706. Pop. 384,736.

Al·bu·quer·que (äl'ba-kūr'ké, äl'ba-kūr'-), Afonso de. "Afonso the Great." 1453–1515. Portuguese colonial administrator considered the founder of the E Portuguese empire.

alc. *abbr.* Alcohol; alcoholic.

Al·cae·us (äl'sē'as). fl. 611?–580 a.c. Greek poet who reputedly invented *Alcaic* verse.

Al·ca·ic (äl-kä'ik) *adj.* Of or relating to a verse form consisting of strophes having four tetrametric lines. [Lat. *Alcaicus*, of *Alcaeus* < Gk. *Alkaios* < *Alkaios*, *Alcaeus*.] — **Al·ca·ic** *n.*

al·cal·de also **al·cay·de** (äl-kä'dē) *n.* The commander or governor of a fortress in Spain or Portugal. [Sp. < Ar. *al-qādī*, the commander: *al*, the + *qādī*, commander (< *qāda*, to command).]

Al·ca·lá·de He·na·res (äl'ka-lä' dā hē-när'as, äl'kä-lä' thē ē-när'as). A town of central Spain ENE of Madrid; birthplace of Cervantes. Pop. 146,994.

al·cal·de (äl-kä'dē, öl-) *n.* The mayor or chief judicial official of a Spanish town. [Sp. < Ar. *al-qādī*: *al*, the + *qādī*, judge (< *qāda*, to judge).]

Al·can Highway (äl'kän'). See *Alaska Highway*.

Al·ca·traz (äl'ka-tráz'). "the Rock." A rocky island of W CA in San Francisco Bay; a military prison from 1859 to 1933 and a federal prison until 1963.

al·caz·ar (äl'kär'ar, -kä'zar, äl'ka-zär') *n.* A Spanish palace or fortress, originally one built by the Moors. [Sp. *alcázar* < Ar. *al-qasr*: *al*, the + *qasr*, castle (< Lat. *castra*, fort, *pl.* of *castrum*, camp; see *kas*·).]

Al·ces·tis (äl'sēs'tis) *n.* Gk. *Myth.* The wife of Admetus, who agreed to die in his place and was later rescued from Hades by Hercules.

al·che·mist (äl'ka-mist) *n.* A practitioner of alchemy. — **al·che·mis'tic**, **al·che·mis'tic·al** *adj.*

al·che·my (äl'ka-mē) *n.* 1. A medieval chemical philosophy having as its asserted aims the transmutation of base metals into gold, the discovery of the panacea, and the preparation of the elixir of longevity. 2. A seemingly magical power or process of transmuting. [ME *alkamis* < OFr. *alquemie* < Med. Lat. *alchemy* < Ar. *al-kīmiyā*: *al*, the + *kīmiyā*, chemistry (< L Gk. *khēmeia*, *khumeia*, perh. < Gk. *Khēmeia*, Egypt).] — **al·chem'i·cal** (äl-kēm'i-kal), **al·chem'ic** *adj.* — **al·che·mize**' (äl'ka-miz') *v.*

Al·ci·bi·ades (äl'sä-bi'ä-dēs'). 450?–404 a.c. Athenian politician and general who changed allegiance three times during the Peloponnesian War (431–404).

Al·cin·dor (äl-sin'dor), Lew. See *Kareem Abdul-Jabbar*.

Alc·me·na (älk-mē'nä) *n.* Gk. *Myth.* Amphitryon's wife and mother of Hercules by Zeus.

al·co·hol (äl'ka-höl', -höl') *n.* 1. A colorless, volatile, flammable liquid, C₂H₅OH, synthesized or obtained by fermentation of sugars and starches and used as a solvent and in drugs and intoxicating beverages. 2. Intoxicating liquor containing alcohol. 3. Any of a series of hydroxyl compounds having the general formula C_nH_{2n+1}OH, including ethanol and methanol. [Med. Lat., fine metallic powder, esp. of antimony < Ar. *al-kuhl*: *al*, the + *kuhl*, powder of antimony.]

Word History: The *al* in *alcohol* may alert some readers to the fact that this is a word of Arabic descent, as is the case with *algebra* and *alkali*. *Al* is the Arabic definite article cor-

Albi
—
ali



albatross
Top: Wandering albat
Diomedea exulans
Bottom: Laysan albat
Diomedea immutabilis



alcazar
Segovia, Spain

ä pat	oi boy
ä pay	ou out
är care	öb took
ä father	öb boot
ä pet	ü cut
ä be	ür urge
i pit	th thin
i ple	sh this
ir pter	hw which
ö pot	zh vision
ö toe	ä about
ö paw	itern

Stress marks:
' (primary);
' (secondary), as in
dictionary (dik'sha-när)

9-833637
#5

PATENT OFFICE
JAPANESE GOVERNMENT

This is to certify that the annexed is a true copy of the following application
as filed with this Office.

Date of Application: April 14, 2000

Application Number: 2000-113913.

Applicant(s): GHEN CORPORATION

NISSHIN FLOUR MILLING CO., LTD.

Dated this 20 th day of April, 2001

Commissioner,
Patent Office

Kozo OIKAWA (Seal)

Certificate Issuance No. 2001-3033309

(Translation)

[Document Name] PETITION FOR PATENT APPLICATION

[Regulation Number] G1X61P

[Destination] Commissioner, Patent Office

[International Patent Classification] A61K 35/12
A23L 1/03

[Inventor]

[Address] c/o GHEN CORPORATION, Immunity Laboratory, 839-1, Sano, Gifu-shi,
Gifu-ken, Japan

[Name] Yoshikatsu KODAMA

[Inventor]

[Address] c/o NISSHIN FLOUR MILLING CO., LTD., Fine Chemicals Research
Laboratory, 3-1, Tsurugaoka 5-chome, Ohimachi, Iruma-gun, Saitama, Japan

[Name] Nobutake KIMURA

[Applicant]

[Identification Number] 000129976

[Address] 296-1, Oritate, Gifu-shi, Gifu, Japan

[Name] GHEN CORPORATION

[Applicant]

[Identification Number] 000226998

[Address] 25, Kanda-Nishiki-cho 1-chome, Chiyoda-ku, Tokyo, Japan

[Name] NISSHIN FLOUR MILLING CO., LTD.

[Agent]

[Identification Number] 100081352

[Patent Attorney]

[Name] Shoichi Hirose

[Fee Expression]

[Prepayment Register Number] 000365

[Payment Amount] 21000

[List of Filed Articles]

[Article Name]	Specification	1
----------------	---------------	---

[Article Name]	Figure	1
----------------	--------	---

[Article Name]	Abstract	1
----------------	----------	---

[Necessity of Proof] Necessary

(Translation)

[Document Name] SPECIFICATION

[Title of the Invention] GLYCOPROTEIN HAVING INHIBITORY ACTIVITY AGAINST
HELICOBACTER PYLORI COLONIZATION

5 [Claims]

[Claim 1] A glycoprotein which specifically binds to urease of Helicobacter pylori, which glycoprotein is obtained by isolation and purification from a glycoprotein-containing substance using a method which utilizes specific adsorption to Helicobacter pylori urease.

10 [Claim 2] The glycoprotein according to Claim 1, wherein the method which utilizes specific adsorption to Helicobacter pylori urease is affinity chromatography using a column on which the urease is immobilized.

~ [Claim 3] The glycoprotein according to Claim 2, wherein the urease of Helicobacter pylori which is immobilized on the column is recombinant urease.

15 [Claim 4] The glycoprotein according to any one of Claims 1 - 3, wherein the glycoprotein-containing substance is a substance derived from whey of bovine milk.

[Claim 5] The glycoprotein according to Claim 4, wherein the glycoprotein-containing substance is high-molecular-weight whey protein concentrate derived from whey of bovine milk.

20 [Claim 6] The glycoprotein according to any one of Claims 1 - 3, wherein the glycoprotein-containing substance is high-molecular-weight albumen protein concentrate derived from the albumen of chicken eggs.

[Claim 7] An inhibitor of Helicobacter pylori colonization, comprising as an active ingredient the glycoprotein according to any one of Claims 1 - 6.

25 [Claim 8] A pharmaceutical composition for preventing and/or treating peptic ulcers, comprising as an active ingredient the glycoprotein according to any one of Claims 1 - 6.

[Claim 9] A food which prevents and/or treats peptic ulcers, comprising the glycoprotein according to any one of Claims 1 - 6.

30 [Claim 10] An inhibitor of Helicobacter pylori colonization, comprising as an active ingredient the glycoprotein according to any one of Claims 1 - 6 and an inhibitor of gastric acid secretion.

[Claim 11] A pharmaceutical composition for preventing and/or treating peptic ulcers, comprising as an active ingredient the glycoprotein according to any one of Claims 1 - 6 and an inhibitor of gastric acid secretion.

[Detailed Description of the Invention]

5 [0001]

The present invention relates to a glycoprotein which is capable of eradicating from the stomach Helicobacter pylori, which is associated with the occurrence of peptic ulcers. It also relates to an inhibitor of the colonization of Helicobacter pylori comprising the glycoprotein, and a medicament and food comprising the inhibitor.

10 [Technical Field of the Invention]

[0002]

[Prior Art]

At present it is believed that eradication of H. pylori from the stomach is essential for fully treating peptic ulcers. The combination of an antibiotic and an inhibitor of gastric acid secretion has been generally proposed as a therapy for eradication of H. pylori as described below.

[0003]

H. pylori is a gram-negative spiral rod-shaped bacterium having flagella at one end and colonizing the human gastric mucosa. B.J. Marshall and J.R. Warren in Australia reported in 1983 that this bacterium was frequently detected in stomach biopsy specimens from patients with gastritis or gastric ulcers. At that time, this bacterium was named Campylobacter pylori since it resembles Campylobacter in morphology and growth characteristics. Later, it was found that the bacterium is different from Campylobacter in the fatty acid composition of its outer membrane and sequence of ribosome 16S-RNA. Therefore, the bacterium is now referred to as Helicobacter pylori and belongs to the newly established genus of Helicobacter.

[0004]

Since then, many reports have been published based on epidemiological studies, indicating that this bacterium causes gastritis, gastric ulcers, and duodenal ulcers and is associated with diseases such as gastric cancer. Once H. pylori colonizes gastric mucosa, it survives and persists in the stomach and cannot be eradicated, although the immune response to infection thereof is strong, i.e., the antibody titer is high. Therefore, unless H. pylori is

completely eliminated from the stomach by antibiotic therapy, the infection will return to the same level as before treatment within about a month after the administration of antibiotics is stopped. Additionally, the pH of the stomach is maintained very low by HCl, which is a strong acid, and therefore most antibiotics tend to be inactivated. For this reason, the combination of an antibiotic and a proton pump inhibitor which strongly suppresses the secretion of gastric acid is utilized for eradication of H. pylori. However, the administration of antibiotics for a long time has the serious problems of increasing antibiotic-resistant strains as well as causing side effects.

[0005]

Japanese Patent Application Kokai No.11-262731 discloses that milk fat globule membrane fraction is effective for prevention of H. pylori infection. However, that publication merely teaches the ability to inhibit haemagglutination of H. pylori as evidence of prevention of H. pylori infection. Additionally, that publication states that milk fat globule membrane contains various components and does not state that which component is effective. Also, Siiri Hirno et al. states that gastric mucin and milk glycoprotein, specifically fat globule membranes prepared from bovine buttermilk inhibit sialic acid-specific haemagglutination of H. pylori (FEMS Immunol. Medical Microbiology 20 (1998), pp. 275-281). However, it has been reported that there was no correlation between expression of haemagglutinins by H. pylori bacteria and the ability to bind gastric mucosa cells (M. Clyne & B. Drumm, Infection and Immunity, Oct. 1993, pp.4051-4057). Accordingly, the above-mentioned patent publication and article do not teach or suggest a substance which is capable of inhibiting the adherence of H. pylori to gastric mucosa.

[0006]

Furthermore, the above patent publication and article have not elucidated an adhesin for adherence of H. pylori to gastric mucosa and a receptor therefor on gastric mucosa, which are important targets for inhibition of H. pylori infection.

[0007]

As described above, there have been many problems such that administration of antibiotics for a long time causes increasing antibiotic-resistant strains as well as side effects.

[Subject to be Solved by the Invention]

[0008]

It is an object of the present invention to provide an effective and safe inhibitor of H. pylori colonization which is associated with the occurrence of peptic ulcers, which inhibitor is

capable of inhibiting the colonization of H. pylori effectively without the disadvantages of side effects and increase of drug-resistant strains which are associated with the use of antibiotics, and to provide a medicament and food useful for treating or preventing peptic ulcers.

[0009]

[Means for Solving the Subject]

Generally, the first step for establishment of an infection by a bacterium is adherence of the bacterium to a host cell and colonization of the bacterium by growing there. For the bacterium to adhere to the host cell, an adhesin has to bind to a receptor on the surface of the host cell. The specificity of the infective site of the bacterium is determined by this adhesin and the receptor. If the receptor molecule exists when the bacterium adheres to the host cell, competitive inhibition occurs and an infection is not established.

[0010]

An adhesin of H. pylori and a receptor on human gastric mucosa are thought to be target molecules for inhibition of H. pylori infection. The present inventors clarified by studies on the mechanism of adherence of H. pylori that the adhesin of H. pylori, which had not been elucidated, is urease produced by H. pylori (Japanese Patent Application Kokai No. 10-287585).

[0011]

The present inventors have studied substances capable of inhibiting the adherence of urease to gastric mucosa and have found that glycoproteins such as glycoprotein derived from the milk of a cow or glycoprotein derived from the albumen of a chicken egg are able to eliminate colonized H. pylori in the stomach by specifically binding to urease which is an adhesin localized on the surface layer of an H. pylori cell, and furthermore have found that the use of glycoprotein capable of specifically binding to urease even in a small amount, which glycoprotein is isolated and purified from these glycoprotein-containing substances by utilization of specific binding to urease, enables remarkably effective elimination of H. pylori.

According to the present invention, glycoprotein which is capable of specifically binding to urease is isolated and purified from a glycoprotein-containing substance by the affinity column technique which utilizes the specific binding to H. pylori urease, and the isolated and purified glycoprotein is used as an inhibitor of H. pylori colonization.

[0012]

In one aspect, the present invention provides a glycoprotein which specifically binds to

urease of Helicobacter pylori, the glycoprotein being obtained by isolation and purification using a method utilizing specific adsorption to Helicobacter pylori urease.

In another aspect, the present invention provides an inhibitor of Helicobacter pylori colonization, comprising the above-mentioned glycoprotein as an active ingredient. The present invention also provides a pharmaceutical composition suitable for preventing or treating peptic ulcers, comprising the above-mentioned glycoprotein as an active ingredient. Furthermore, the present invention provides a food which prevents or treats peptic ulcers, comprising the above-mentioned glycoprotein.

[0013]

The method utilizing specific adsorption to Helicobacter pylori urease used in the present invention is preferably affinity chromatography using a column on which Helicobacter pylori urease is immobilized. The urease which is immobilized on the column may be recombinant urease.

[0014]

[Form for Carrying out the Invention]

Details of the present invention will be described below.

According to the present invention, a glycoprotein which specifically binds to urease is isolated and purified from a glycoprotein-containing substance by a method utilizing specific adsorption to H. pylori urease.

[0015]

Glycoprotein-containing substances used in the present invention may be any glycoprotein-containing substance such as the milk of a mammal or the albumen, chalaza, vitelline membrane or yolk of eggs of a fowl. Preferably, the whey of bovine milk and the albumen of chicken eggs, particularly high-molecular-weight whey protein concentrate and high-molecular-weight albumen protein concentrate are used.

[0016]

Glycoprotein is a conjugated protein in which sugar chains consisting of about 2-6 types of monosaccharides are bound covalently to proteins. It is distributed widely in organisms. The monosaccharides contained in glycoprotein are N-acetyl-D-glucosamine, N-acetyl-D-galactosamine, D-mannose, D-galactose, L-fucose, sialic acid, etc. There are various types of glycoproteins having different molecular weights and configurations. From the standpoint of

forms of linkage between sugar chains and proteins, there are generally two types of glycoproteins, i.e., N-linked glycoproteins and O-linked glycoproteins (mucin type). Types of sugar chains, molecular weights and configurations of glycoproteins as well as functions or physiological activities vary depending on the location of glycoproteins existed.

5 [0017]

Glycoproteins contained in bovine milk include lactoferrin, secretory IgA, IgG, IgM, free secretory component (FSC), milk mucin and the like. Glycoproteins contained in the albumen of a chicken egg include ovomucoid, ovalbumin, ovotransferrin, phosvitin, ovomucin and the like.

[0018]

10 In preparing a glycoprotein-containing substance, any known method can be used. A glycoprotein-containing substance may be prepared from bovine milk, for example, by removing milk fat and casein from milk in a conventional manner to obtain whey followed by fractionation concentration of the whey by appropriate means such as ultrafiltration membrane treatment to obtain high-molecular-weight whey protein concentrate (glycoprotein-containing
15 substance). A glycoprotein-containing substance may be also prepared by removing lipoprotein from the whey, optionally followed by concentration and dialysis, and subsequently purifying the resulting material by suitable means such as gel filtration using a Sepharose column, etc., and treatment with a membrane. Optionally, further treatment such as protease treatment, alkali hydrolysis, etc. may be performed in order to obtain low-molecular-weight glycoprotein. Bovine
20 milk used in the present invention may be either colostrum or milk produced following colostrum.

[0019]

A glycoprotein-containing substance may be prepared from the albumen of chicken eggs by the following procedures, for example. Thick albumen is separated from collected albumen.
25 A gelatinous portion is recovered by ultracentrifugation and is solubilized by techniques such as ultrasonic wave treatment or homogenization. The resulting solubilized substance is treated by gel filtration, membrane treatment or any other techniques to obtain a glycoprotein-containing substance. The thus obtained glycoprotein-containing substance may be further purified, if necessary, by a procedure such as gel filtration.

30 [0020]

A glycoprotein-containing substance from the mucous membrane or gel layer thereof in

the alimentary canal may be usually recovered by solubilizing glycoprotein by homogenization or ultrasonic wave treatment and then isolating the high molecular weight fraction by gel filtration or ethanol precipitation. Solubilization of a glycoprotein-containing substance may be performed by extraction with guanidine hydrochloride, urea, a salt solution, or a surfactant or treatment with a reducing reagent or protease. Some kinds of glycoprotein-containing substances may be recovered by forming an insoluble complex with a quaternary ammonium salt or by precipitation under acidic conditions.

[0021]

Advantageously, bovine milk or the albumen of chicken eggs is used as a starting material of a glycoprotein-containing substance, since these materials can be obtained inexpensively and in large quantities, and the preparation of a glycoprotein-containing substance therefrom can be carried out easily and by a simple procedure. Also, in preparing a glycoprotein-containing substance from milk, milk whey can be used. In the past, milk whey has been discarded since there was no effective way of using it, although it is produced in large amounts as by-product during a process for preparing cheese and the like. Therefore, a glycoprotein-containing substance from whey can be prepared in large amounts industrially, and the use of a glycoprotein-containing substance from milk is very advantageous with respect to cost and practicality.

[0022]

Additionally, glycoprotein in bovine milk or the albumen of chicken eggs is of high stability and does not lose its physiological activity due to heat or at a low pH, and therefore it can be readily recovered and purified from a starting material, and it is advantageous with respect to formulation into a food or medicament, processing, and storing.

[0023]

Any method which utilizes specific adsorption to urease can be used for isolation and purification of glycoprotein which specifically binds to H. pylori urease from a glycoprotein-containing substance. Preferably, affinity chromatography using a column on which H. pylori urease is immobilized is used. As urease which is immobilized on a column, recombinant urease may be preferably used because of the availability of homogeneous urease in large amounts.

[0024]

Recombinant urease may be prepared in a conventional way. For example, genomic DNA of H. pylori can be extracted, and a gene coding urease molecule can be amplified by PCR method to obtain amplified DNA, which can be subsequently integrated into expression vector for E. coli (e.g. pKK233-2) by a known method. The obtained vector can be incorporated into a suitable host, E.coli (e.g. E.coli XL1-Blue) to produce recombinants. The recombinants can be cultured in a suitable culture medium, thereby expressing urease. Recombinant urease can be obtained by recovering the expressed urease. In preparing recombinant urease, expression systems using yeasts, mammal cells and insect cells may be used. Procedures for preparing recombinant urease are described, for example, in Molecular Cloning, Laboratory Annual (2nd ed.) (Cold Spring Harbor Press), and in DNA Cloning 2 (2nd ed.) (IRL Press).

[0025]

Immobilization of urease on a column may be performed using a ligand-immobilizing carrier which is capable of binding an amino group (-NH₂), carboxyl group (-COOH), thiol group (-SH), or hydroxyl group (-OH) contained in urease (e.g. NHS-activated Sepharose 4 Fast Flow). Isolation and purification of glycoproteins by a urease-immobilized column may be carried out by passing a sample containing a glycoprotein-containing substance through this column, followed by washing away non-specifically adsorbed proteins, and then eluting glycoproteins, which have specifically adsorbed to urease, from the column with an appropriate eluting solution.

[0026]

According to the above-mentioned method, only glycoprotein which specifically binds to urease can be isolated and purified efficiently from various types of glycoprotein-containing substances. The thus obtained glycoprotein can inhibit the adherence of urease produced by H. pylori to mucin of gastric mucosa as demonstrated in the following examples. Since urease is localized on the surface of H. pylori cells, the glycoprotein produced by the above-mentioned method which specifically binds to urease (hereinafter referred to as the glycoprotein of the present invention) masks the adhesin i.e., urease, by predominantly binding to urease in the stomach and thereby inhibits the adherence of H. pylori to the receptor on gastric mucosa. This was confirmed in animal experiments, and the effect of the glycoprotein of the present invention on elimination of H. pylori from the stomach was observed. Also, the glycoprotein of the present invention is naturally-occurring and is very safe. Therefore, the glycoprotein of the

present invention can be used as an inhibitor of H. pylori colonization in the stomach and is useful for preventing or treating diseases caused by or associated with H. pylori such as peptic ulcers.

[0027]

5 Accordingly, the glycoprotein of the present invention can be used as an inhibitor of H. pylori colonization to be formulated into a medicament or food. Especially, the glycoprotein from milk or albumen of chicken eggs has been eaten in the past, so it can be formulated into foods such as foods for specified health use having anti H. pylori activity, foods for special dietary uses including foods for the aged or foods for the ill, or dietary supplement foods or
10 health foods having anti H. pylori activity.

[0028]

When the glycoprotein of the present invention is added to foods to be used as foods for specified health use or as foods for special dietary uses, the glycoprotein may be added to foods, usually in an amount of about 0.005-0.5 % by weight, and preferably 0.01-0.1 % by weight of
15 the food. Foods for specified health uses to which the glycoprotein of the present invention is added include milk, dairy products, meat products, mayonnaise, dressings, beverages, ice cream, tofu (soybean curd), daily dishes, tsukudani (preserved foods boiled down in soy sauce), bean jams, flour paste, instant noodles, powdered food to be sprinkled over rice, pickled vegetables, powdered soups, dehydrated soups, confections, canned foods, retort pouched foods, frozen
20 foods, and the like. Among these, foods which can be consumed continuously are preferred, but not required. When added to foods for the ill such as low sodium food, low energy food, or low protein food, the glycoprotein of the present invention may be added to soups, beverages, liquid diets, etc. to prepare foods in various forms.

[0029]

25 Dietary supplement foods may be prepared, for example by adding to the glycoprotein of the present invention excipients such as dextrin, adhesives such as sodium caseinate, and, if necessary, nutrients (e.g. vitamins, minerals), emulsifiers, stabilizers, flavors, and the like to prepare a liquid diet.

[0030]

30 When the glycoprotein of the present invention is utilized as a health food, the glycoprotein may be contained as an active ingredient in an amount of about 0.1-3 % by weight

of the food. The glycoprotein may be formulated together with excipients such as lactose, corn starch, crystalline cellulose, or PVP, or with binders, and optionally with nutrients such as vitamins and minerals to form various forms of foods such as fine particles, tablets, and granules.

5 [0031]

The glycoprotein of the present invention can be used alone or along with conventional additives as a pharmaceutical composition for prevention or treatment of peptic ulcers, etc. The glycoprotein alone or along with additives may be formed by a conventional method into a preparation for oral administration such as tablets, granules, powders, capsules or liquid
10 preparations. The additives which may be used include excipients, binder, disintegrators, lubricants, antioxidants, coloring materials, corrigents, and the like.

[0032]

Excipients which can be used in a pharmaceutical composition include sodium carboxymethylcellulose, agar, light anhydrous silicic acid, gelatin, crystalline cellulose, sorbitol,
15 talc, dextrin, starch, lactose, sucrose, glucose, mannitol, magnesium metasilicate aluminate, calcium hydrogenphosphate, and the like.

[0033]

Binders which can be used include gum arabic, sodium alginate, ethanol, ethyl cellulose, sodium caseinate, sodium carboxymethylcellulose, agar, purified water, gelatin, starch,
20 tragacanth, lactose, hydroxycellulose, hydroxymethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidon, and the like.

[0034]

Disintegrators which can be used include carboxymethylcellulose, sodium carboxymethylcellulose, calcium carboxymethylcellulose, crystalline cellulose, starch,
25 hydroxypropylstarch, and the like.

[0035]

Lubricants which can be used include stearic acid, calcium stearate, magnesium stearate, talc, hydrogenated oil, sucrose fatty acid ester, wax, and the like.

[0036]

30 Antioxidants which can be used include tocopherol, gallic acid ester, dibutyl hydroxy toluene (BHT), butyl hydroxy anisol (BHA), ascorbic acid, and the like.

[0037]

Other additional additives or agents may be added if desired, such as antacids (e.g., sodium hydrogencarbonate, magnesium carbonate, precipitated calcium carbonate, synthetic hydrotalcite), agents for protection of gastric mucosa (e.g., synthetic aluminum silicate, sucralfate, and sodium copper chlorophyllin) and digestive enzymes (e.g., biodiastase or lipase).

[0038]

The administration of a pharmaceutical composition for prevention or treatment of peptic ulcers, etc. may be by an oral route. The dosage of the glycoprotein of the present invention will be usually 2-30 mg and preferably 5-20mg (as a dry weight) per day for an adult.

10 [0039]

Additionally, the above-mentioned pharmaceutical composition for prevention or treatment of peptic ulcers, etc. may further comprise an inhibitor of gastric acid secretion. The combination of the glycoprotein and the inhibitor of gastric acid secretion is more effective in eliminating *H. pylori* from the stomach. Examples of an inhibitor of gastric acid secretion which can be used include H_2 blockers such as famotidine, nizatidine, roxatidine, ranitidine or cimetidine and proton pump inhibitors such as omeprazol, lansoprazol or sodium rabeprazole. — The dosage of the inhibitor of gastric acid secretion is preferably 20-30 mg per day for an adult.

[0040]

The following examples are given to further illustrate the present invention. It should be understood that the present invention is not limited to the specific details set forth in the examples.

[0041]

[Example]

Example 1

25 (1) Preparation of Recombinant Urease of *H. pylori*

Genomic DNA of *H. pylori* strain TU130 was extracted, and the DNA coding urease molecule was amplified by the PCR method. The amplified DNA was integrated into expression vector pKK233-2 (Amersham Pharmacia Biotec) to obtain vectors to be used for expressing urease. The vector was incorporated into *E. coli* XL1-Blue to obtain *E. coli* capable of expressing urease. The recombinant bacteria were cultured with shaking at 100 rpm at 37 °C in 1.0 liter of LB medium containing 100 μ g/ml of ampicillin. When the bacterial cells reached a

logarithmic growth phase, isopropyl- β -D-thiogalactopyranoside (IPTG) was added at a concentration of 0.5 mM in order to induce expression, and the cells were further cultured with shaking overnight under the same conditions as above. The *E. coli* cells were harvested by centrifugation at 4,000 x g for 20 minutes (+4°C).

5 [0042]

The obtained cells were suspended in tris buffer for lysis (50 mM Tris-HCl (pH 8.0), 100 mM NaCl, 1 mM EDTA). After addition of lysozyme at a concentration of 0.1 mg/ml, the suspension was allowed to stand in ice for 30 minutes. Then, the suspension was frozen at -80°C for more than 1 hour, and was thawed at room temperature. The suspension was treated by ultrasonic wave, and Triton X-100 was added at a concentration of 1 %. Inclusion bodies of recombinant urease were collected by centrifugation at 30,000 x g for 30 minutes (+4°C), .

[0043]

These inclusion bodies were suspended in a buffer for washing inclusion bodies (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA containing 0.1 % SDS, 1.0 % Triton X-100, 0.1 % sodium deoxycholate) and centrifuged at 30,000 x g for 10 minutes (+4°C). The precipitated inclusion bodies were further washed twice in the same manner. These inclusion bodies were solubilized by suspending them in 8 M urea solution (8 M urea, 50 mM Tris-HCl (pH 8.0), 1 mM EDTA, 1 mM DTT) and then allowing the suspension to stand at room temperature for 1 hour. After the resulting suspension was centrifuged at 30,000 x g for 30 minutes (+4°C), the supernatant was dialyzed against 100-fold volume of 20 mM phosphate buffer supplemented with 1 mM EDTA (pH 6.5), thereby renaturing the configuration of urease to obtain recombinant urease-containing substance to be purified.

[0044]

For purification of the above recombinant urease-containing substance, Cellulofine sulfate-m (Chisso Inc.) was equilibrated with 10 gel bed volumes of 20 mM phosphate buffer supplemented with 1 mM EDTA (pH 6.5). 50 ml of this substance readjusted to pH 6.5 was applied to the above Cellulofine sulfate-m equilibrated with 20 mM phosphate buffer supplemented with 1 mM EDTA (pH 6.5), and then 20 mM phosphate buffer (pH 6.5) supplemented with 1 mM EDTA was passed through the gel. Combined fractions having a peak containing urease were adjusted to pH 5.5 and were applied to Cellulofine sulfate-m preequilibrated with 10 gel bed volumes of 20 mM phosphate buffer supplemented with 1 mM

EDTA (pH 5.5). After that, the gel was washed with 20 mM phosphate buffer (pH 5.5). Then, urease was extracted by passing 20 mM phosphate buffer, pH 7.4 containing 0.15 M NaCl through the gel. Combined fractions containing urease were dialyzed against a 100-fold volume of distilled water and were lyophilized to form powdered recombinant urease. The obtained recombinant urease were confirmed to be the same as natural urease of H. pylori by SDS-PAGE and western blotting.

[0045]

(2) Preparation of Column Containing Immobilized Recombinant Urease of H. pylori

2 g of NHS-activated Sepharose 4 Fast Flow (Amersham Pharmacia Biotec Inc.) were suspended in about 50 ml of 1 mM HCl and were swelled at room temperature for 15 minutes. The swelled gel was subjected to filtration with suction on a glass filter and washed twice with a 10-fold volume of 1 mM HCl. Then, the gel was suspended in 50 ml of coupling buffer (0.1 M NaHCO₃, 0.5 M NaCl, pH 8.8) and filtered with suction on a glass filter. 10 mg of powdered purified recombinant urease as prepared in above (1) were dissolved in 10 ml of coupling buffer. The resulting solution was immediately mixed with the gel, and was allowed to react overnight at 4°C with gentle shaking by a shaker.

[0046]

After the reaction mixture was removed by suction filtration, the resulting gel was suspended in blocking buffer (0.2 M glycine, pH 8.3) and was left overnight at 4°C with gentle shaking to block the residual reactive groups. After the gel was filtered with suction on a glass filter, it was washed successively with 50 ml of coupling buffer, 50 ml of washing buffer (0.1 M acetic acid, 0.5 M NaCl, pH 4.0), and 100 ml of 20 mM phosphate buffer supplemented with 0.5 M NaCl (pH 7.0). The resulting gel was suspended in an approximately 5-fold volume of 20 mM phosphate buffer, pH 5.5 containing 0.5 M NaCl, which was directly poured into a column to fill it. The column was transferred to a low temperature room and was equilibrated with 3 bed volumes of 20 mM phosphate buffer, pH 5.5 containing 0.1 M NaCl, which is used as a column containing immobilized recombinant urease of H. pylori for isolating the glycoprotein of the present invention.

[0047]

(3) Preparation of High-Molecular-Weight Whey Protein Concentrate from Bovine Milk Whey

20 liter of bovine milk was centrifuged at 2,000 x g at 4°C for 15 minutes so as to

remove milk fat, and the supernatant was recovered. Then, to the supernatant, 1M acetic acid was added dropwise until the pH was 4.6 so as to remove casein. After the supernatant was allowed to stand for 1 hour at room temperature, casein was removed by centrifugation to obtain bovine whey. Then, the whey, which was adjusted to a pH of 6, was fractionated by
5 ultrafiltration for 1000,000 Da to be concentrated to one-twentieth volume, and high-molecular-weight whey protein concentrate was obtained.

[0048]

(4) Preparation of High-Molecular-Weight Albumen Protein Concentrate from Albumen of Chicken Eggs

10 From 50 unfertilized eggs of White Leghorn hens within a week after being laid, only albumen was collected and was sieved to separate thick albumen, which was suspended in Mensel buffer (pH 9.5, ionic strength=0.01) and was solubilized by ultrasonic wave treatment at 10 W and 9 kHz(+2°C) for 10 minutes. This solubilized product was fractionated by an ultrafiltration membrane for 300,000 Da of fractionational molecular weight to be concentrated
15 to one-twentieth volume, and high-molecular-weight albumen protein concentrate was obtained.

[0049]

(5) Isolation of Urease Specifically-Binding Glycoprotein Using Urease-Immobilized Column

One liter of each of the high-molecular-weight protein concentrates prepared in the above procedures (3) and (4) was adjusted to pH 5.5. The following procedures were conducted in a
20 low temperature room. The urease-immobilized column prepared in the above procedure (2) was preequilibrated with 10 bed volumes of 20 mM phosphate buffer containing NaCl (pH 5.5). Each sample mentioned above was passed through this column. Then, the column was swept with 10 bed volume of 20 mM phosphate buffer containing 0.5 M NaCl (pH 5.5) to remove non-specifically adsorbed proteins. Glycoproteins which specifically had bound to urease in the
25 column were eluted from the column with 20 mM phosphate buffer containing 0.5 M NaCl (pH 7.4). After dialysis with 100-fold distilled water followed by lyophilization, the glycoprotein of the present invention, i.e., H. pylori urease- specifically binding glycoprotein was obtained approximately one gram at a time.

[0050]

30 Experiment 1 In vitro Experiment

Inhibitory effects on adherence of urease produced by H. pylori to gastric mucosa were

examined in an in vitro experiment system using high-molecular-weight whey protein concentrate prepared by the above-described procedure (3), high-molecular-weight albumen protein concentrate prepared by procedure (4), and the glycoprotein of the present invention prepared by procedure (5) of Example 1.

5 [0051]

(Materials and Methods)

The present inventors had already found that an adhesin of H. pylori is urease produced by H. pylori. Since this urease binds well to mucin of gastric mucosa, porcine gastric mucin prepared as follows was used for urease adherence test.

10 [0052]

Preparation of Porcine Gastric Mucin

Healthy pigs about two months old were slaughtered, and their stomachs were recovered and washed on the insides thereof with 0.1 M phosphate buffer (pH 7.4) containing 0.15M NaCl, 5mM N-ethyl maleimide (NEM), 1mM phenylmethylsulfonyl fluoride (PMSF) and 1mM
15 EDTA. The stomachs were incised, and the gastric mucosa was scraped and suspended in the above-mentioned buffer. This suspension of mucosa was homogenized by a Polytron homogenizer while being iced and was centrifuged at 15,000 x g to recover a supernatant. The supernatant was centrifuged again at 25,000 x g to recover a supernatant, which was dialyzed against distilled water and lyophilized to obtain crude gastric mucin. Then, this lyophilized
20 crude gastric mucin was dissolved in 0.1 M phosphate buffer (pH 6.8) containing 0.15 M NaCl, 6M guanidine hydrochloride and protease inhibitor (5mM NEM, 1mM PMSF, 1mM EDTA), and overlaid on a cesium chloride density gradient (1.5 g/ml) and centrifuged at 34,000 x g for 48 hours. A sialic acid-containing fraction was detected by nitrocellulose membrane blotting and dyeing with periodic acid Schiff's reagent. Dyed fractions were pooled and overlaid on a
25 cesium chloride density gradient and centrifuged. Dyeing-positive fractions were pooled and lyophilized. Then, the lyophilized product was subjected to gel filtration through a Sepharose CL-4B column preequilibrated with 0.1M phosphate buffer (0.1M NaCl, pH 6.8) to carry out fractionation. Fractions which were PAS dyeing-positive and had proteins at a high concentration were pooled and dialyzed against PBS (pH 6.8) to obtain purified porcine gastric
30 mucin, which was stored at -80°C until use. The obtained gastric mucin was confirmed to be glycoprotein of 66kD by SDS-PAGE.

[0053]

Urease Adherence Test to Porcine Gastric Mucin

A microplate for a urease adherence test was prepared as follows.

To each well of a 96-well microplate, a 50 µl portion of purified porcine gastric mucin
5 (1.27 mg/ml) was added to each well and was subjected to immobilization by standing overnight
at 4°C. When the microplate is used for urease adherence test, blocking is conducted by adding
3% BSA to each well to react at 37°C for 60 minutes, and then the plate was washed three times
with 20 mM phosphate buffer containing 0.15 M NaCl and 0.05% Tween 20.

[0054]

10 A urease adherence test was carried out using the microplate prepared above in order to
observe adherence of urease to porcine gastric mucin immobilized on the microplate, as follows.

Native urease prepared from H. pylori strain TU130 and recombinant urease prepared by
procedure (1) of Example 1 were biotinylated and the biotinylated urease was diluted so as to
give a final concentration of 7.0 µg/ml with adhesion media consisting of 20 mM phosphate
15 buffer containing 0.15 M NaCl and 0.05 % Tween 20 having different pH ranges (pH
preadjusted to be 2.0, 3.0, 4.0, 4.5, 5.0, 5.5, 6.0 or 6.5). Each urease sample thus prepared was
added to 2 wells of mucin-immobilized microplate mentioned above to conduct sensitization at
37°C for 60 minutes. Then, in order to determine the amount of urease adhered to the well,
streptoavidin HRP was added to each well to react at 37°C for 60 minutes. Then, ortho-
20 phenylenediamine 2HCl as a substrate and H₂O₂ were added to react. 3N H₂SO₄ was used for
termination of the reaction. Known amounts of biotinylated urease diluted serially 2-fold were
placed in a running plate and a calibration curve thereof was used to determine the amount of
urease in a sample.

[0055]

25 Inhibition Test of Urease Adherence

Inhibition tests of urease adherence were conducted using the glycoprotein of the present
invention (Procedure (5) of Example 1), high-molecular-weight whey protein concentrate
(Procedure (3) of Example 1), and high-molecular-weight albumen protein concentrate
(Procedure (4) of Example 1). First, samples having various concentrations were each mixed
30 with biotinylated porcine gastric mucin, and each mixture was transferred to a well of a 96-well
plate immobilized with urease and sensitized at 37°C for 60 minutes. Then, each well in the

microplate was washed five times with adhesion medium (pH 4.0) and was fixed by heating at 65°C for 10 minutes. The fixed wells were washed once with adhesion medium (pH 7.0), and streptoavidin HRP was added to each well to detect biotinylated porcine gastric mucin adhered to urease by ELISA as described above.

5 [0056]

(Results)

Urease Adherence Pattern to Purified Porcine Gastric Mucin

As shown in Fig. 1, native urease and recombinant urease adhere specifically to porcine gastric mucin, and this adherence pattern depends on pH. Since urease adherence reaction at about pH 3.0 is considered to reflect the colonization characteristics of H. pylori in gastric mucosa, a substance which is able to inhibit the adherence of urease in this pH range may inhibit the colonization of H. pylori in the stomach. Since recombinant urease exhibits the same adherence properties as native urease, the glycoprotein of the present invention when purified using a column on which recombinant urease is immobilized is thought to inhibit the colonization of H. pylori in the stomach by masking urease of H. pylori.

15 [0057]

Inhibition of Urease Adherence by Glycoprotein of the Present Invention

As shown in Fig. 2, urease adherence to porcine gastric mucin was inhibited dose-dependently with high-molecular-weight whey protein concentrate, high-molecular-weight albumen protein concentrate and the glycoprotein of the present invention purified from each of the protein concentrates. The glycoprotein of the present invention exhibited about 100 % inhibitory activity even at a low concentration, which is a remarkably high efficacy. Urease is localized on the surface of H. pylori cells, and therefore the urease-binding glycoprotein of the present invention can inhibit infection with H. pylori, i.e., it can eliminate H. pylori from the stomach by binding to urease of the H. pylori cells and masking the urease, an adhesin, in the stomach.

Experiment 2 In vivo experiment

This experiment was performed in an animal model to further confirm the results of Experiment 1.

30 [0058]

(Method)

The experimental animals were hairless mice (NS:Hr/ICR, Research Institute for Human and Animal Propagation, Accession No. IRA-NHI-9701) (ATCC #72024) (Clin. Diagn. Lab. Immunol. 5: 578-582, 1998) having a high sensitivity to H. pylori infection. Each mouse was challenged with 1×10^9 CFU of strain NSP 335 by oral administration. After breeding for a week, the mice were administered the glycoproteins of the present invention added to feeds at various concentrations for 4 weeks. Another group was administered the glycoprotein of the present invention along with an H_2 blocker (famotidine) or a proton pump inhibitor (omeprazol). There were 10 mice in each group. After the completion of administration of the samples, the mice in each group were slaughtered. The stomachs of the mice were recovered, and after removal of the contents, the whole mucous membrane was homogenized by a homogenizer to form an emulsion, which was used for detection of H. pylori. The detection of H. pylori was carried out by placing the emulsion on a medium for detecting H. pylori (Poremedia H. pylori isolation medium, Eiken Kagaku), incubating at 37°C for 5 days by the gas pack method, and counting colonies.

[0059]

(Results)

Effects of Glycoprotein of the Present Invention on elimination of H. pylori in H. pylori-colonized mice

As shown in Fig. 3, the glycoprotein of the present invention could eliminate H. pylori from the stomach in a concentration-dependent manner. The elimination rate was 100 % at the maximum dose (20 μ g/ml) and 70-75 % at the minimum dose (1 μ g/ml), which is remarkably high elimination rate corresponding to in vitro experiment results. 100% of mice (10/10) in the control group were infected with H. pylori. From these results, it is thought that the glycoprotein of the present invention can inhibit infection with H. pylori by binding predominantly to urease produced by H. pylori and masking the urease, an adhesin. Also, the combination of the glycoprotein and an inhibitor of gastric acid secretion showed enhanced efficacy.

[0060]

Below, examples of various preparations are given. The glycoprotein used in the examples is the glycoprotein prepared by procedure (5) of Example 1.

Preparation 1 (Food)

(Chewing gum)

	gum base	25.0
	calcium carbonate	2.0
	sorbitol	54.0
	mannitol	16.0
5	flavor	1.0
	glycoprotein	1.0
	<u>water q.s. to 100.0 (% by weight)</u>	
	(ice cream)	
	cream (40% fat content)	33.97
10	milk (3.7% fat content)	33.16
	defatted evaporated milk	16.08
	sugar	11.75
	corn syrup	4.67
	stabilizer	0.3
15	<u>glycoprotein</u>	<u>0.02</u>
	total	100.0 (% by weight)
	[0061]	

Preparation 2 (Foods for special dietary uses)

(powdered soup)

20	powdered bean for cooking	67.5
	wheat flour	3.9
	wheat embryo	2.5
	dry yeast powder	2.5
	onion powder	4.8
25	meat extract powder	15.5
	salt	0.2
	spices (white pepper, etc.)	1.8
	seasonings (amino acid, etc.)	0.2
	<u>glycoprotein</u>	<u>0.1</u>
30	total	100.0 (% by weight)

(dried soup) 10.0 g/200 ml

	chicken egg	4.0
	meat extract	1.3
	onion extract	1.73
	carrot paste	2.16
5	kombu extract	0.1
	emulsifier	0.1
	salt	0.2
	spice (red pepper)	0.2
	seasonings (amino acid, etc.)	0.2
10	<u>glycoprotein</u>	<u>0.01</u>
	total	10.0 g

[0062]

Preparation 3 (Health Food)

Formula 1: in 100 g of fine particles

15	glycoprotein	1 g
	lactose (200M)	59 g
	corn starch	35 g
	PVP (K-30)	5 g

These components were formulated into fine particles by a conventional wet granulation
20 method.

Formula 2: in 100 g of granules

	glycoprotein	2 g
	lactose (200M)	60 g
	corn starch	33 g
25	PVP (K-300)	5 g

These components were formulated into granules by a conventional extrusion granulation
method.

[0063]

Preparation 4 (Dietary supplement foods)

30 liquid food (200 ml/pack)

	glycoprotein	0.01
--	--------------	------

	maltodextrin	39.0
	casein Na	13.0
	vegetable oil	12.0
	vitamins	1.0
5	minerals	1.5
	emulsifier	0.2
	milk protein	10.3
	sodium phosphate	1.8
	potassium phosphate	1.2
10	flavor	0.5
	stabilizer (carrageenan)	1.5
	<u>water</u>	<u>q.s. to 100.0 (% by weight)</u>

Tonic (soup type)

	glycoprotein	0.02
15	carrot (carrot paste)	10.0
	heavy cream	12.0
	lactose	1.8
	onion (onion extract)	1.5
	milk protein powder	0.5
20	milk oligosaccharide	1.5
	consomme powder	0.5
	wheat embryo	0.5
	eggshell calcium	0.2
	whey calcium	0.1
25	salt	0.2
	emulsifier	0.2
	<u>water</u>	<u>q.s. to 100.0 (% by weight)</u>

[0064]

Preparation 5 (Medicen)

30 Formula 1: in 1.5 kg of fine particles
glycoprotein 15 g

lactose	1,100 g
corn starch	340 g
PVP (K-30)	45 g

These components were granulated by a wet granulation method, followed by drying
5 and forming into fine particles in a conventional way.

Formula 2: tablets

1.glycoprotein	15 g
2.lactose	400 g
3.corn starch	150 g
10 4.crystalline cellulose	210g
5.PVP (K-300)	25 g
6.magnesium stearate	10g

The above components 1-5 were formulated into granules by a wet granulation method,
magnesium stearate was then added to form powders for preparing tablets, and then these
15 powders were compressed into tablets (200 mg/tablet).

[0065]

Formula 3: in 1.5 kg of granules

glycoprotein	20 g
lactose (200M)	950 g
20 corn starch	480 g
PVP (K-30)	50 g

These components were mixed intimately and granulated by an extrusion granulation
method, followed by drying and forming into granules in a conventional way.

[0066]

25 Formula 4: in 1.5 kg of fine particles

glycoprotein	15 g
famotidine	20g
lactose	1,100 g
corn starch	320 g
30 PVP (K-30)	45 g

These components were granulated by a wet granulation method, followed by drying and

forming into fine particles in a conventional way.

[0067]

Formula 5: tablets

	1.glycoprotein	20 g
5	2.famotidine	20g
	3.lactose	400 g
	4.corn starch	135 g
	5.crystalline cellulose	200g
	6.PVP (K-300)	25 g
10	7.magnesium stearate	10g

The above components 1-6 were formulated into granules by a wet granulation method, magnesium stearate was then added to form powders for preparing tablets, and then these powders were compressed into tablets (200 mg/tablet).

[0068]

15 Formula 6: in 1.5 kg of granules

	glycoprotein	20 g
	famotidine	30g
	lactose (200M)	950 g
	corn starch	450 g
20	PVP (K-30)	50 g

These components were granulated by an extrusion granulation method, followed by drying and forming into granules in a conventional way.

[0069]

[Effect of the Invention]

25 As is apparent from the above, in accordance with the present invention, a safe and effective inhibitor of H. pylori colonization and a food and medicament containing the inhibitor are provided. Since the glycoprotein which specifically binds to urease as an adhesin is isolated and purified from a glycoprotein-containing substance and used in the present invention, the adherence of H. pylori to gastric mucosa can be blocked effectively even when a small amount
30 of the glycoprotein is used. Therefore, diseases caused by H. pylori such as peptic ulcers can be suppressed effectively without the occurrence of side effects. Unlike antibiotics which have

been used for treatment of peptic ulcers, the glycoprotein of the present invention can eliminate H. pylori specifically from the stomach without producing drug-resistant bacteria. As a starting material of the glycoprotein of the present invention, milk and chicken eggs, which can be obtained inexpensively and in large amounts, may be used to prepare in a simple manner a glycoprotein which exhibits superior effects.

[Brief Description of the Drawings]

[Figure 1]

Fig. 1 is a graph showing adherence patterns of urease to purified porcine gastric mucin.

[Figure 2]

Fig. 2 is a graph showing the inhibition rate of urease adherence.


[Figure 3]

Fig. 3 is a graph showing the elimination rate of H. pylori in H. pylori-colonized mice.


[Document Name]

FIGURE

[Figure 1]




[Figure 2]



— GLYCOPROTEIN FROM MILK WHEY
--- GLYCOPROTEIN FROM ALBUMEN
-.- HIGH-MOLECULAR-WEIGHT WHEY PROTEIN CONCENTRATE
... HIGH-MOLECULAR-WEIGHT ALBUMEN PROTEIN CONCENTRATE

[Figure 3]



[Document Name]

ABSTRACT

[Summary]

[Problem] To obtain a safe and effective inhibitor of H.pylori colonization, and a food and medicin for preventing or treating peptic ulcers etc., comprising the inhibitor.

5 [Means for Solving the Problem] A glycoprotein which specifically binds to urease of H.pylori is isolated and purified from a glycoprotein-containing substance, especially that obtained from whey of bovine milk or the albumen of chicken eggs, by the affinity chromatography using a column on which H.pylori urease is immobilized. This glycoprotein can inhibit effectively the colonization of H.pylori, and can be used in a food or as a medicin for
10 preventing or treating peptic ulcers.

[Figure Selected] None